| Document |
Document Title |
|
WO/2024/012569A9 |
The present disclosure relates to the biopharmaceutical field, in particular, to a linker for preparing targeting molecule-drug conjugates, and the corresponding conjugates, the preparing process and use thereof.
|
|
WO/2024/043251A1 |
The present invention addresses the problem of providing a method for predicting the cell membrane permeability of a cyclic peptide that enables the versatile design of cell membrane permeable cyclic peptides. The present invention provi...
|
|
WO/2024/034200A1 |
Disclosed are a highly rigid peptide linker inserted between a transmembrane protein and an organelle transport signal, a fusion protein containing the same, and a localization method that includes inserting a peptide linker.
|
|
WO/2024/029630A1 |
The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure pertains to a compound for neural cell activity regulation. More specifically, the compound of the pr...
|
|
WO/2024/024565A1 |
The present invention addresses the problem of providing an agent that suppresses cell aging and a drug that prevents or treats diseases and the like caused by cell aging. More specifically, the present invention is a cell aging suppress...
|
|
WO/2023/100158A9 |
The application relates to fluorescence-quenched substrates of Formula (I) for an acid β-glucosidase (GCase) and their use in a method for determining GCase activity in a cell or tissue, a method for localizing GCase activity within a c...
|
|
WO/2023/230077A1 |
A system and method of using contrastive language-image pre-training (CLIP) to devise a unified, sequence-based framework to design target-specific peptides via contrastive learning. In one or more further implementations, using known ex...
|
|
WO/2023/210774A1 |
Provided is a compound that includes a peptide structure represented by formula (p1) or (p2). Also provided is a method for producing a droplet using the compound. Xa is an amino acid residue having a hydrophilic side chain. Xb is an ami...
|
|
WO/2023/212322A2 |
Nanostructured chiral microparticles with bowtie shape having widely variable pitch, size, thickness and length are provided. The self-limited assembly of anisotropic building blocks makes possible high synthetic reproducibility, size mo...
|
|
WO/2023/183059A1 |
The present invention provides a method of treating pathological inflammation in a patient comprising: administering to the patient a multivalent structured polypeptide comprising at least one therapeutic peptide. The present invention a...
|
|
WO/2023/178327A1 |
Described are peptides comprising a membrane translocation domain having one or more cell penetrating peptide motifs, where at least one cell penetrating peptide motif is from 3 to 10 amino acid residues in length and has at least three ...
|
|
WO/2023/163227A1 |
The present invention provides a linker, a linker/payload, an antibody-drug conjugate, and an antitumor drug that are novel. Specifically, the present invention provides an antibody-drug conjugate that is represented by general formula (...
|
|
WO/2023/163234A1 |
The present invention provides: a method for improving the stability of an antibody-drug conjugate in vivo; and a conjugate precursor for producing a stabilized antibody-drug conjugate. More specifically, the present invention provides: ...
|
|
WO/2023/127503A1 |
This invention relates to a method for changing hydrogel volume, the method comprising: a step A for bringing an ionic polymer into contact with a hydrogel, which has a site having decomposition activity for the ionic polymer and a cross...
|
|
WO/2022/221144A9 |
Embodiments of the claimed invention are directed to synthetic peptides comprising an amino acid sequence of X1X2VX3NLRGDLQVLX4QKVCX5T (SEQ ID NO:18), wherein at least one of X1 and X2 is a cysteine, and wherein one or more of X3, X4, an...
|
|
WO/2023/068327A1 |
The present invention addresses the problem of: providing a method for reliably chemogenetically controlling the activity of a protein, and providing a protein used in this method. Specifically, the present invention is a plurality of pr...
|
|
WO/2023/058527A1 |
A compound represented by formula (1) [in formula (1): Xaa, Xaa1, Xaa2 and Xaa3 independently represent an arbitrary amino acid residue; n represents an integer of 1-20; R is nil or represents a straight-chain or branched sugar chain con...
|
|
WO/2023/042875A1 |
The present invention addresses the problem of providing: a gel formation kit which can be used for the production of a non-human animal and enables the formation of a tumor with high efficiency within a short period of time in the produ...
|
|
WO/2023/032994A1 |
Provided are a compound and a labeled biomaterial, the compound having a phosphor part and a structure represented by general formula (I). In general formula (I), A1 denotes a structure represented by general formula (a1), A2 denotes a s...
|
|
WO/2023/032996A1 |
A compound which has at least two phosphor parts and a structure represented by general formula (I), and a labeled biomaterial. In the formula, X1 to X3 represent -O-, -S-, >NR1 or >CR2R3. R1 to R3 represent a hydrogen atom or a substi...
|
|
WO/2023/032995A1 |
This compound has two or more fluorescent portions that are equivalent in terms of light-absorbing characteristics. In the compound, the fluorescent portions adjacent to each other are linked via a group having a structure represented by...
|
|
WO/2023/008321A1 |
Provided is a method for identifying an unknown splicing peptide derived from a known parent peptide included in a biological sample, wherein the method includes: (1) a first step for obtaining mass spectrometry data pertaining to peptid...
|
|
WO/2023/277186A1 |
Provided is a means that makes it possible to simultaneously and accurately analyze a target peptide, a component derived from a carrier for liquid phase peptide synthesis, and the like. Provided is a method for simultaneously analyzin...
|
|
WO/2023/276967A1 |
Provided is a novel polymer composition exhibiting osmoregulatory activity. Provided particularly is an osmolyte which can inhibit protein alteration, etc. in lower concentrations. This osmoregulator is characterized by comprising a po...
|
|
WO/2022/234851A1 |
It has been discovered that a large binding selectivity for the RAS(G12D) mutant is possessed by a binding molecule that has the following characteristic features: (i) direct interaction with the Asp12 in the RAS(G12D) mutant and (ii) in...
|
|
WO/2022/218331A1 |
Provided herein are a linker molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof.
|
|
WO/2022/217490A1 |
A method for preparing a collagen peptide. The method comprises the following steps: pre-treating fish skin and fish meat, then adding 0.5 monl/L of a glacial acetic acid solution and pepsin with a mass fraction of 3%, stirring the mixtu...
|
|
WO/2022/194238A1 |
There is provided a conjugate formed between an anaesthetic compound and a peptide component of the amino acid sequence: W-Lys-X 1-Ser-U-X 2-Y wherein: W, X 1, U, X 2 and Y are as defined in the description, as well as regioisomers, ster...
|
|
WO/2022/193185A1 |
Provided are a conjugate formed between an anaesthetic compound and a peptide component of the amino acid sequence:W-Lys-X1-Ser-U-X2-Y, wherein:W, X1, U, X2 and Y are as defined in the description, as well as regioisomers, stereoisomers,...
|
|
WO/2022/149584A1 |
The present invention provides a peptide having a fluoroalkyl group as a side chain. The present invention pertains to a peptide in which two or more amino acids are peptide-bonded, wherein at least one of the amino acid residues constit...
|
|
WO/2022/109163A1 |
Controlled release biodegrading microcapsules comprising polypeptide chains.
|
|
WO/2022/097500A1 |
A protein or peptide crosslinking agent which is represented by formula (I). [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, or a phenyl group.]
|
|
WO/2022/065173A1 |
Provided are: a membrane-permeable molecule which has a structure represented by general formula (i) and forms a salt with an acid having a pKa value greater than -8.0 and less than 4.7; and a method for improving the membrane permeabili...
|
|
WO/2022/065172A1 |
A cell membrane-permeable molecule which has a structure represented by general formula (I) and which is in the form of a salt with an acid having a pKa value of lower than 4.7; and a method of improving the cell membrane permeability of...
|
|
WO/2022/054625A1 |
Provided is a complex containing a pyrrole-imidazole polyamide that recognizes a particular DNA sequence and binds thereto and containing peptide that contains 1-5 arginine residues.
|
|
WO/2021/235494A1 |
Provided is a medical agent that exerts preventative and therapeutic effects against viral infections, by inhibiting proteases of viral origin on the basis of the effects of various physiological activities of an active sulfur compound p...
|
|
WO/2021/231920A1 |
The present disclosure relates to methods of writing data in nucleic acid chains and methods of reading data written in nucleic acid chains. The present disclosure also relates to a kit for writing and reading data in nucleic acid chains.
|
|
WO/2021/156331A2 |
The invention relates to use of ionic polymers (IP) consisting of anions and a polymeric backbone containing cations, in hydrolyzing proteins and protein-containing feedstock to produce protein hydrolysates.
|
|
WO/2021/155354A1 |
A method for the prevention, treatment, or amelioration of a medical disease or condition associated with inflammation caused by glutamate excitotoxicity comprising administering to a patient a peptide that binds to or interferes with th...
|
|
WO/2021/136475A1 |
A linker molecule for targeting molecule-drug conjugate, has the structure of formula (I): A1p-D1q-Y-Lk-W-A2q-D2p (I). A conjugate has the structure of formula (III): A-((compound of formula (I))-PL t) z (III). The conjugate can be used ...
|
|
WO/2021/108919A1 |
A method and system for generating a protein sequence is implemented using a computer-implemented neural network. An empty or partially filed sequence of node elements, representing amino acid positions of the protein sequence, and an ed...
|
|
WO/2021/106706A1 |
The present invention improves the accuracy of searching for an amino acid sequence of interest. An information processing device (amino acid sequence searching device) 1 is provided with: a storage unit 17 that stores a trained model fo...
|
|
WO/2021/058660A1 |
The present invention is directed to an anti-adsorption solution for the analysis of peptides. Also a process for the preparation of such an anti-adsorption solution and the use of said anti-adsorption solution are described.
|
|
WO/2021/055696A1 |
Single-module nonribosomal peptide synthetases (NRPSs) and NRPS-like enzymes activate and transform carboxylic acids in both primary and secondary metabolism; and are of great interest due to their biocatalytic potentials. The single-mod...
|
|
WO/2021/047648A1 |
Provided is a peptide compound comprising the amino acid sequence: G-W-Lys-X1-Ser-U-X2-Y-Z-Q wherein: G represents an optional N-terminal a 3, 4-dihydrocinnamic acid group; W represents Ala or Ser, or is absent; U represents Tyr, DOPA or...
|
|
WO/2021/010316A1 |
The present invention addresses the problem of providing an N-substituted amino acid-containing peptide and a method for producing a protein binding factor using the peptide. More specifically, the present invention pertains to a peptide...
|
|
WO/2020/262555A1 |
A side effect reducing agent for a nucleic acid drug that comprises an oligopeptide containing an oligopeptide domain, said oligopeptide domain consisting of 2-40 amino acids and including a structure W that has two or more specific cons...
|
|
WO/2020/226438A1 |
The present invention relates to a peptide for preventing or treating inflammatory bowel diseases. The peptide of the present invention exhibits excellent effects in preventing or treating inflammatory bowel diseases and thus can be extr...
|
|
WO/2020/213568A1 |
Disclosed is a method for producing a polymerized polypeptide aggregate, said method comprising a step for reacting a polypeptide, which has a tag on the N-terminal side and/or C-terminal side, with a polymerase to give a reaction liquid...
|
|
WO/2020/203626A1 |
The present invention provides a biologically-related substance to which a branched degradable polyethylene glycol derivative being decomposed in cells and being represented by formula (A) below is bound. (In the formula, each symbol is ...
|
